CoChat

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Open access
Awad, Mark M., Gadgeel, Shirish M., Borghaei, Hossein, Patnaik, Amita, Yang, James Chih-Hsin, Powell, Steven F., Gentzler, Ryan D., Martins, Renato G., Stevenson, James P., Altan, Mehmet, Jalal, Shadia I., Panwalkar, Amit, Gubens, Matthew, Sequist, Lecia V., Saraf, Sanatan, Zhao, Bin, Piperdi, Bilal, Langer, Corey J. · 2021 · Journal of Thoracic Oncology
Cited by 172

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

INTRODUCTION In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective response rate (ORR) and progression-free survival (PFS) versus chemotherapy alone with manageable toxicity in advanced nonsquamous non‒small-cell lung cancer (NSCLC). We report long-term outcomes from this study. METHODS Patients with previously untreated advanced nonsquamous NSCLC without sensitizing EGFR/ALK alterations were randomly assigned 1:1 to receive open-label pemetrexed 500 mg/m2 plus carboplatin AUC 5 mg/mL/min (4 cycles) with or without pembrolizumab 200 mg (up to 2 years), with optional pemetrexed maintenance, each administered every 3 weeks. Eligible patients could cross over from the chemotherapy arm to pembrolizumab monotherapy after progression. Responses were assessed per RECIST v1.1. RESULTS After 49.4-months median time from randomization to data cutoff, ORR (58% vs 33%) and PFS (median, 24.5 vs 9.9 months; HR, 0.54; 95%CI, 0.35‒0.83) remained improved with pembrolizumab combination (n=60) versus chemotherapy (n=63), regardless of PD-L1 status. Median OS was 34.5 versus 21.1 months (HR, 0.71; 95%CI, 0.45‒1.12), despite a 70% crossover rate from chemotherapy alone to anti‒PD-(L)1 therapy. Among the 12 patients who completed 2 years of pembrolizumab, 92% were alive at data cutoff; the estimated 3-year DOR rate was 100%. Grade 3‒5 treatment-related adverse events occurred in 39% of patients receiving pembrolizumab combination and 31% receiving chemotherapy. CONCLUSIONS First-line pembrolizumab plus pemetrexed-carboplatin continued to show improved response and survival versus chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.09.015

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Awad, M. M., Gadgeel, S. M., Borghaei, H., Patnaik, A., Yang, J. C.-H., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Altan, M., Jalal, S. I., Panwalkar, A., Gubens, M., Sequist, L. V., Saraf, S., Zhao, B., Piperdi, B., & Langer, C. J.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-01
Volume
16
Issue
1
Pages
162-168
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3093317346
Cited by
172
References
2
FWCI
8.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.